Market News & Trends
Anavex Life Sciences Initiates Placebo-Controlled US Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Anavex Life Sciences Corp. recently announced the first patient in its US FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX3-71 for the treatment of…
Sequel’s twiist Automated Insulin Delivery System Receives FDA 510(k) Clearance
Device bundles latest technology to deliver significant advancements for insulin management for people with type 1 diabetes….
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
BioXcel Therapeutics, Inc. recently reported the European Patent Office (EPO) granted the company’s European Patent No. 3,562,486 on March 13, 2024. The 486 patent covers…
Curia Appoints Steve Lavezoli as Vice President, Biologics
Curia, a leading contract research, development and manufacturing organization, recently announced it has appointed Steve Lavezoli as Vice President of Biologics effective Feb. 26. Lavezoli…
Atrogi Announces Positive Clinical Data From First-in-Class Insulin-Independent Treatment for Type 2 Diabetes
Atrogi recently announced the full set of results from its Phase 1 a/b trial with ATR-258, its first-in-class treatment for type 2 diabetes (T2D). This…
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Cleavable capping technology confines therapeutic activity to the local tumor micro environment which increases the anticipated therapeutic window in patients….
Noramco Announces Strategic Alignment With Purisys & Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API & Drug Product Supply Chain Services Provider
Noramco recently announced its launch of the Noramco Group, a newly created comprehensive North American-based supply chain solution including subsidiaries Purisys, Noramco, and the newly acquired….
Lirum Therapeutics Announces Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against IGF-Related Cancers
Lirum Therapeutics, Inc. recently announced the acceptance for presentation of positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin-like growth factor…
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T Cell Modulators
GRI Bio, Inc. recently announced the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. 3,007,970 titled, Prevention and…
SciSparc Achieves Major Milestone With First Patient Dosed in Autism Spectrum Disorder Clinical Trial
SciSparc Ltd. recently announced it has successfully dosed the first patient in its SCI-210 clinical trial at the Soroka Medical Center for pediatric patients who…
Almirall & Eloxx Pharmaceuticals Enter Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall, S.A. and Eloxx Pharmaceuticals, Inc. recently announced the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall…
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
Terns Pharmaceuticals, Inc. recently announced the US FDA granted Orphan Drug Designation for TERN-701 for the treatment of chronic myeloid leukemia (CML). TERN-701, the Company’s…
Cellares Unveils First cGMP-Compliant Cell Shuttle in its South San Francisco Center of Excellence
Cellares recently announced the completion of its first current Good Manufacturing Practice (cGMP)-compliant Cell Shuttle. The Cell Shuttle is an automated, ultra-high throughput, cell therapy…
Alcami Partners With Tanvex to Offer a Complete Solution for Biologics Developers
Alcami Corporation recently announced a new strategic partnership with Tanvex CDMO, a biologics developer offering pre-clinical to commercial biologic CDMO services. Through the collaboration, Alcami…
Moa to Develop Next-Gen Bioherbicides in New 10-Year Commercial Partnership With Croda
Deal will accelerate Moa’s development of next-generation bioherbicides, designed to tackle the global threat to food production from increasing weed resistance….
Ajinomoto Bio-Pharma Services Garners Six CDMO Leadership Awards, Further Establishing its Industry Excellence
Ajinomoto Bio-Pharma Services recently received CDMO Leadership Awards in all six categories - Capabilities, Compatibility, Expertise, Quality, Reliability, and Service for both the Overall and…
Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics
Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics….
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for First-in-Class NEK7 Directed Molecular Glue Degrader & NLRP3/IL-1β Pathway Inhibitor
Monte Rosa Therapeutics, Inc. recently announced a novel development candidate, MRT-8102, a potent, highly selective and orally bioavailable NIMA related kinase 7 (NEK7)-directed MGD. MRT-8102…
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
Immuneering Corporation recently announced the first patient has been dosed in the Phase 2a portion of its Phase 1/2a clinical trial of IMM-1-104, its lead…
Acelyrin Announces Positive Top-line Results From Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
ACELYRIN, INC. recently announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16…
